← Back to Screener
Shattuck Labs, Inc. Common Stock (STTK)
Price$7.53
Favorite Metrics
Price vs S&P 500 (26W)300.49%
Price vs S&P 500 (4W)11.57%
Market Capitalization$538.88M
All Metrics
Book Value / Share (Quarterly)$1.30
P/TBV (Annual)0.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)15.44%
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)102.16%
Net Profit Margin (TTM)-1005.60%
EPS (TTM)$-0.77
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-0.77
Revenue Growth (5Y)-36.82%
EPS (Annual)$-0.70
ROI (Annual)-59.24%
Net Profit Margin (5Y Avg)-5460.38%
Cash / Share (Quarterly)$1.23
Revenue Growth QoQ (YoY)-66.63%
ROA (Last FY)-53.62%
Revenue Growth TTM (YoY)-82.52%
EBITD / Share (TTM)$-0.69
ROE (5Y Avg)-57.74%
Operating Margin (TTM)-1071.60%
Cash Flow / Share (Annual)$-0.63
P/B Ratio6.54x
P/B Ratio (Quarterly)2.80x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)484.69x
Net Interest Coverage (TTM)-3.43x
ROA (TTM)-58.65%
EPS Incl Extra (Annual)$-0.70
Current Ratio (Annual)11.70x
Quick Ratio (Quarterly)11.07x
3-Month Avg Trading Volume0.61M
52-Week Price Return897.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.65
P/S Ratio (Annual)538.88x
Asset Turnover (Annual)0.01x
52-Week High$7.68
Operating Margin (5Y Avg)-5631.28%
EPS Excl Extra (Annual)$-0.70
CapEx CAGR (5Y)-37.25%
26-Week Price Return309.24%
Quick Ratio (Annual)11.07x
13-Week Price Return59.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.70x
Enterprise Value$484.687
Revenue / Share Growth (5Y)-42.92%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-29.38%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4880.90%
Cash / Share (Annual)$1.23
3-Month Return Std Dev69.68%
Net Income / Employee (TTM)$-1
ROE (Last FY)-59.24%
EPS Basic Excl Extra (Annual)$-0.70
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.77
ROI (TTM)-65.03%
P/S Ratio (TTM)538.88x
Pretax Margin (5Y Avg)-5460.38%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$4.16
Price vs S&P 500 (52W)862.12%
Year-to-Date Return106.30%
5-Day Price Return11.23%
EPS Normalized (Annual)$-0.70
ROA (5Y Avg)-51.17%
Net Profit Margin (Annual)-4880.90%
Month-to-Date Return17.11%
Cash Flow / Share (TTM)$-2.14
EBITD / Share (Annual)$-0.69
Operating Margin (Annual)-5150.80%
ROI (5Y Avg)-57.74%
EPS Basic Excl Extra (TTM)$-0.77
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)2.80x
Pretax Margin (TTM)-1005.60%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)56.33%
Beta1.11x
Revenue / Share (TTM)$0.01
ROE (TTM)-65.03%
52-Week Low$0.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
STTKShattuck Labs, Inc. Common Stock | 538.88x | -82.52% | — | — | $7.53 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Shattuck Labs develops novel antibody therapeutics for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a potentially first-in-class DR3 antagonist antibody for inflammatory bowel disease, with a pipeline including SL-425 (an extended half-life variant) and bispecific antibodies based on its protein engineering platform.